Saccharomyces boulardii Does Not Prevent Relapse of Crohn's Disease Arnaud Bourreille, Guillaume Cadiot, Gérard Le Dreau, David Laharie, Laurent Beaugerie, Jean–Louis Dupas, Philippe Marteau, Patrick Rampal, Dominique Moyse, Ashraf Saleh, Marie–Emmanuelle Le Guern, Jean–Paul Galmiche  Clinical Gastroenterology and Hepatology  Volume 11, Issue 8, Pages 982-987 (August 2013) DOI: 10.1016/j.cgh.2013.02.021 Copyright © 2013 AGA Institute Terms and Conditions

Figure 1 Flow chart of the patients screened and randomized in the study. Clinical Gastroenterology and Hepatology 2013 11, 982-987DOI: (10.1016/j.cgh.2013.02.021) Copyright © 2013 AGA Institute Terms and Conditions

Figure 2 Patients with clinical relapse at follow-up according to the stratification factor. Patients in stratum S were initially treated with salicylates (N = 28), and patients in stratum C had received corticosteroids (N = 131). Clinical Gastroenterology and Hepatology 2013 11, 982-987DOI: (10.1016/j.cgh.2013.02.021) Copyright © 2013 AGA Institute Terms and Conditions

Figure 3 Survival remission curves of patients treated with S boulardii or placebo (Kaplan–Meier estimate from week 4 to week 52). The median time to relapse was 40.7 weeks in the S boulardii group and 39.0 weeks in the placebo group (P = .78). Clinical Gastroenterology and Hepatology 2013 11, 982-987DOI: (10.1016/j.cgh.2013.02.021) Copyright © 2013 AGA Institute Terms and Conditions